<DOC>
	<DOCNO>NCT00767533</DOCNO>
	<brief_summary>To learn whether Interferon defect cell signaling , recently discover immune cell melanoma patient well breast cancer patient , common cancer .</brief_summary>
	<brief_title>Immunobiology Cancer</brief_title>
	<detailed_description>BACKGROUND We previously demonstrate tumor-specific T cell could identify &gt; 50 % patient metastatic melanoma cell appear rendered anergic vivo [ Nature Medicine 5:677 , 1999 ] . Recently discover signal defect Interferon ( IFN ) pathway immune cell melanoma patient [ PLOS Medicine 4:897 2007 ] . Interestingly , preliminary study show defect immune cell breast cancer patient ( unpublished ) . We would like expand research type cancer determine whether phenomena occur different cancer type . OBJECTIVES Our primary objective determine whether IFN signal defect different type cancer determine cause defect . The second objective determine whether PBMCs render anergic . INVESTIGATIONAL PLAN The study population consist patient diagnose cancer , regardless sex ethnicity . Blood collect subject regularly schedule laboratory appointment peripheral blood mononuclear cell ( PBMCs ) isolate research purpose . These PBMCs undergo study , i.e . phosflow , qPCR , proliferation , survival , etc. , determine immune response T cell ( CD4 CD8 ) , B cell ( CD19 ) , natural killer cell ( CD16 ) , possibly monocyte ( CD14 ) .</detailed_description>
	<criteria>Participants cancer participant cancer and/or autoimmune disorder age 18 . Participants autoimmune disorder and/or age 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>